Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

By Jean-Pierre Pignon, H. Tribodet, G. Scagliotti, J. Douillard, F. Shepherd, R. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour and 7 more. Journal of Clinical Oncology, 2008

2,400 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a0be2162b3c599db04dfe35b188c0155f849ff20

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer (2013, methodology): “A previous meta-analysis of all the trials investigating chemotherapy benefit demonstrated a 5% improvement in overall survival [28].”
Lung cancer: Biology and treatment options. (2015, background): “To date, adjuvant platinum-based chemotherapy was shown to be beneficial for stage II NSCLC patients [77] and is the recommended treatment strategy for completely resected patients [72].”
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, positive): “Individual patient data meta-analysis affirmed the beneficial effects of cisplatin-based chemotherapy per subgroup of patients with lung cancer, and it is recommended for stages II–III [24] [I, A].”
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution (2017, background): “Does the cell number 109 still really fit one gram of tumor tissue? Cell 480 Cycle 2009;8(3):505-6.”
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling (2017, background): “N Engl J Med 2017;376(22):2109-21 doi 10.”